Patienter behandlet med rekombinant koagulationsfaktor VIII bør med passende klinisk observation og laboratorie tests overvåges nøje med henblik på udvikling af inhibitorer.
Patients treated with recombinant coagulation factor VIII should be carefully monitored for the development of inhibitors by appropriate clinical observations and laboratory tests.